Company: BGLC
Filing Date: 2025-12-03
Form Type: DEF 14A
Source: 0001477932-25-008757
Chunk: 32

Company: BioNexus Gene Lab Corp
Filing Date: 2025-12-03
Form: DEF 14A
Chunk 32
---
 Plan-Based Awards</div>

Except as stated above, no plan-based awards were granted to any of our named executive officers during the fiscal year ended December 31, 2024.

<div align='center'>Policies and Practices Regarding the Timing of Awards of Options</div>

During the fiscal year ended December 31, 2024, the Company did not maintain an equity incentive plan or other equity compensation arrangements. As a result, the Company did not grant any stock options to named executive officers during the fiscal year, and the Board of Directors did not maintain a specific policy regarding the timing of equity awards in relation to the release of material non-public information.

Subject to shareholder approval of Proposal 2 (the "2025 Equity Incentive Plan"), the Compensation Committee intends to adopt policies to ensure that future equity grants are made in accordance with applicable laws and best practices regarding the release of material non-public information.

<div align='center'>Outstanding Equity Awards at Fiscal Year End</div>

The equity awards reflected in the Summary Compensation Table above represents all restricted stock awards issued to our executive officers as of December 31, 2024. No other stock or stock option awards were granted to any other officer of the Company as of December 31, 2024.

<div align='center'>Option Exercises and Stock Vested</div>

No option to purchase our capital stock was exercised by any of our named executive officers, nor was any restricted stock held by such executive officers vested during the fiscal period ended December 31, 2024.

<div align='center'>Pension Benefits</div>

No named executive officers received or held pension benefits during the fiscal period ended December 31, 2024.

| 24 |

<div align='center'>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</div>

The following table sets forth certain information known to us as of November 28, 2025 except where another date is noted below), with respect to beneficial ownership of our Common Stock by (i) each person (or group of affiliated persons) who is known by us to own beneficially more than five percent (5%) of our outstanding Common Stock, (ii) each director, (iii) each of our named executive officers (NEOs), and (iv) all current directors, executive officers and named executive officers as a group, together with the approximate percentages of outstanding Common Stock owned by each of them. The following table is based upon information supplied by directors, executive officers, other key executives identified